Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG.
Prostate Cancer Prostatic Dis. 2021 Mar 21. doi: 10.1038/s41391-021-00338-z.
Contact: Lisa Butler
Statins and the lipidome in prostate cancer
In a prospective clinical trial across 5 Australian sites, we are giving men with prostate cancer statins (cholesterol lowering drug) to examine whether they reverse a poor prognosis lipidome signature.
ANZ Clinical Trials Register Study ID: ACTRN12617000965303 (NSW Study)
Contact: Professor Lisa Butler
Lipids, metabolomics & prostate cancer
Lipids (fatty acids) can profoundly influence prostate cancer cell behaviour, including disease aggressiveness and resistance to drugs. We are using this knowledge to i) develop sensitive probes for lipid biomarkers to predict disease behaviour and the likely response of men to different prostate cancer drugs to better guide treatment and improve health outcomes, ii) evaluate lipid enzyme inhibitors as a novel drug approach for treating prostate cancer, and iii) better inform lifestyle-related prevention strategies to reduce the risk of aggressive disease.
Prostate Cancer Research Group
South Australian Health and Medical Research Institute (SAHMRI), The University of Adelaide
Contact: Professor Lisa Butler